company background image
BCRX

BioCryst Pharmaceuticals NasdaqGS:BCRX Stock Report

Last Price

US$10.76

Market Cap

US$1.9b

7D

11.9%

1Y

-37.2%

Updated

24 Jun, 2022

Data

Company Financials +
BCRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

BCRX Stock Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.

BioCryst Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for BioCryst Pharmaceuticals
Historical stock prices
Current Share PriceUS$10.76
52 Week HighUS$19.99
52 Week LowUS$7.61
Beta2.51
1 Month Change22.27%
3 Month Change-32.71%
1 Year Change-37.19%
3 Year Change183.91%
5 Year Change93.53%
Change since IPO65.54%

Recent News & Updates

Jun 24

BioCryst: A Prudent Diversification

BioCryst Pharmaceuticals shares have been clobbered due to both the bear market and the uncertainty relating to its lead developing drug (BCX9930). I believe that the FDA would remove the partial clinical hold on BCX9930 by either year-end or next year. The lead drug (Orladeyo) is enjoying robust sales increase due to various launched catalysts.

Shareholder Returns

BCRXUS BiotechsUS Market
7D11.9%10.3%6.6%
1Y-37.2%-24.4%-18.5%

Return vs Industry: BCRX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: BCRX underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is BCRX's price volatile compared to industry and market?
BCRX volatility
BCRX Average Weekly Movement15.2%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: BCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BCRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1986358Jon Stonehousehttps://www.biocryst.com

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

BioCryst Pharmaceuticals Fundamentals Summary

How do BioCryst Pharmaceuticals's earnings and revenue compare to its market cap?
BCRX fundamental statistics
Market CapUS$1.89b
Earnings (TTM)-US$193.97m
Revenue (TTM)US$188.03m

10.6x

P/S Ratio

-10.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCRX income statement (TTM)
RevenueUS$188.03m
Cost of RevenueUS$233.35m
Gross Profit-US$45.31m
Other ExpensesUS$148.66m
Earnings-US$193.97m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.05
Gross Margin-24.10%
Net Profit Margin-103.16%
Debt/Equity Ratio-368.1%

How did BCRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX?

Other financial metrics that can be useful for relative valuation.

BCRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.9x
Enterprise Value/EBITDA-11.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BCRX's PS Ratio compare to its peers?

BCRX PS Ratio vs Peers
The above table shows the PS ratio for BCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average92.1x

Price-To-Sales vs Peers: BCRX is good value based on its Price-To-Sales Ratio (10.6x) compared to the peer average (92.1x).


Price to Earnings Ratio vs Industry

How does BCRX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: BCRX is good value based on its Price-To-Sales Ratio (10.6x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is BCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio3.9x

Price-To-Sales vs Fair Ratio: BCRX is expensive based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).


Share Price vs Fair Value

What is the Fair Price of BCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BCRX ($10.76) is trading below our estimate of fair value ($46.48)

Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


68.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCRX's revenue (23.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: BCRX's revenue (23.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has BioCryst Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BCRX is currently unprofitable.

Growing Profit Margin: BCRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.

Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is BioCryst Pharmaceuticals's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BCRX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BCRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BCRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BCRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Jon Stonehouse (60 yo)

15.42yrs

Tenure

US$7,061,225

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining on January 8, 2007 and also has been its President...


CEO Compensation Analysis

Compensation vs Market: Jon's total compensation ($USD7.06M) is about average for companies of similar size in the US market ($USD5.50M).

Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BCRX's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: BCRX's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.


Top Shareholders

Company Information

BioCryst Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BioCryst Pharmaceuticals, Inc.
  • Ticker: BCRX
  • Exchange: NasdaqGS
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.887b
  • Shares outstanding: 185.58m
  • Website: https://www.biocryst.com

Number of Employees


Location

  • BioCryst Pharmaceuticals, Inc.
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham
  • North Carolina
  • 27703
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.